TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07727538: A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants

Sponsor: Ionis Pharmaceuticals, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,272,888

Rescue Site Savings

+$848,592

Unlock Full NCT07727538 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07727538 Rescue Dossier →